Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR NEW INDICATION OF ANAPRAZOLE SODIUM

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group has recently been approved by the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration of the People's Republic of China ("**China**"). to initiate a Phase III clinical trial of bismuth-containing quadruple therapy comprising Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei) for the eradication of Helicobacter pylori.

This Phase III clinical trial is a multi-centre, randomized, double-blind, double-dummy, active-drug parallel-controlled trial, which plans to enroll 556 adult subjects positive for Helicobacter pylori. Using bismuth-containing quadruple therapy containing esomeprazole magnesium as the active control, the trial aims to evaluate the efficacy, safety and population pharmacokinetic characteristics of bismuth-containing quadruple therapy containing anaprazole sodium administered continuously for 14 days for the eradication of Helicobacter pylori. The primary endpoint is the eradication rate of Helicobacter pylori confirmed by ^{13}C-urea breath test ("**^{13}C-UBT**") on day 28 after the completion of treatment.

Helicobacter pylori is a Gram-negative microaerophilic pathogenic bacterium closely associated with a variety of gastric diseases, including gastric ulcer, chronic progressive gastritis and gastric cancer. According to Frost & Sullivan, the infection rate of Helicobacter pylori in China is approximately 44%, and the market size of drugs for the treatment of Helicobacter pylori infection continues to expand. The market size reached RMB5.5 billion in 2024, and is projected to increase to RMB6.8 billion in 2029 and reach RMB12.6 billion in 2035.

The approval of the Phase III clinical trial application for the new indication of Anaprazole Sodium helps to expand the product's indication scope, enhance the Company's influence in the field of digestive disease treatment, and is of great significance to the long-term development and commercialization layout of the Company.

ABOUT ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei) was approved for marketing by the National Medical Products Administration of China in June 2023 for the treatment of patients with duodenal ulcer. Anaprazole Sodium features an innovative structural design with characteristics including non-enzymatic plus multi-enzymatic metabolism and balanced intestinal-renal dual-channel excretion, with only 3.5% metabolized through CYP2C19, making it unaffected by CYP2C19 gene polymorphism. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium has lower risk of drug-drug interactions, making it a safer choice for patients on multiple medications and those with renal impairment, and is a proton pump inhibitor more suitable for the Chinese population. As a Class 1 innovative drug in China, Anaprazole Sodium fills the gap in domestically developed proton pump inhibitors, bringing treatment options with both superior efficacy and safety to Chinese patients. In addition to the approved indication for duodenal ulcer, the phase III clinical study in China of Anaprazole Sodium Enteric-coated Tablets for the treatment of reflux esophagitis was fully launched in July 2025, and has successfully completed the enrolment of all subjects.

This announcement is a voluntary announcement made by the Company for the purpose of keeping its shareholders and potential investors informed of the Group's latest business developments and does not contain any advertisement or intention regarding the use of any drugs, surgical equipment, treatments, or oral products.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, April 15, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.